March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Photobiomodulation as a New Treatment for Dry Age Related Macular Degeneration. Results from the Toronto and Oak Ridge Photobimodulation Study in AMD (TORPA)
Author Affiliations & Notes
  • Graham Merry
    Photospectra Health Sciences Inc, Toronto, Ontario, Canada
  • Robert Dotson
    Photospectra Health Sciences Inc, Oak Ridge, Tennessee
  • Robert Devenyi
    Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada
  • Samuel Markowitz
    Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada
  • Sophia Reyes
    Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada
  • Footnotes
    Commercial Relationships  Graham Merry, Photospectra Health Sciences Inc. (E); Robert Dotson, US Patent 7479136 (P); Robert Devenyi, None; Samuel Markowitz, None; Sophia Reyes, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2049. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Graham Merry, Robert Dotson, Robert Devenyi, Samuel Markowitz, Sophia Reyes; Photobiomodulation as a New Treatment for Dry Age Related Macular Degeneration. Results from the Toronto and Oak Ridge Photobimodulation Study in AMD (TORPA). Invest. Ophthalmol. Vis. Sci. 2012;53(14):2049.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Evaluation of Photobiomodulation as a new treatment for dry age related macular degeneration. This is the first study globally to use low powered Light Emitting Diodes (LEDs) in AMD.

Methods: : IRB approved, prospective study. Subjects with dry AMD were consented and enrolled according to the protocol and outcome measures were assessed before and after the intervention. ETDRS Visual Acuity, Contrast Sensitivity and Fixation Stability (Bivariate contour elliptical area method) were assessed pre treatment, immediately post treatment and at 4, 6 and 12 month intervals.Devices were Warp10 (Quantum Devices) and Gentlewaves (Light Bioscience). Treatment Parameters: Warp10: 670nm +/- 15nm at 50-80 mW/cm2, 4-7.68 J/cm2, for 88 +/- 8 seconds.Gentlewaves: 590nm +/- 8nm at 4mW, 790nm +/- 60nm at 0.6mW, for 30 seconds. Subjects treated 18 times over a six week period with both devices.

Results: : Final data: 18 enrolled eyes. Repeated measures ANOVA for ETDRS Visual Acuity(logMAR): F(4,68) = 18.86, p less than 0.0001 Repeated measures ANOVA for Contrast sensitivity (3cycles/degree): F(4,68) = 11.44, p less than 0.0001 Repeated measures ANOVA for Contrast Sensitivity (1.5 cycles/degree): F(4,68) = 4.39, p less than 0.0032 Repeated measures ANOVA for Fixation Stability (BCEA): F(4,68) = 0.90, p less than 0.4661 Correlation analysis between Fixation Stability and ETDRS VA showed Pearson R value of 0.6776, p less than 0.001

Conclusions: : Statistically significant improvement in Visual Acuity and Contrast sensitivity immediately following the treatment and remaining statistically significant at one year. Fixation stability did not show statistically significant improvement however correlation analysis with Visual acuity did show a significant correlation improvement after the treatment. This is an effective, non invasive, easily administered and safe treatment with no serious adverse events noted.

Clinical Trial: : http://www.clinicaltrials.gov NCT00940407

Keywords: age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×